ICON currently has over 39,000 employees in 138 locations in 53 countries. ICON offers a broad range of specialised services to assist pharmaceutical, biotechnology, medical device and government and public health organisations to bring new treatments to market faster. Our services span the entire lifecycle of product development, across a broad range of therapeutic areas, and can be adapted to suit small local trials or large global programs. We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.ICON services video
Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.
Organic growth bolstered through a number of strategic acquisitions which have broadened our service portfolio and have added scale to existing services.
ICON has assembled a leadership team with extensive industry experience.
ICON's press releases.
Quarter 4 2021 adjusted revenue of $1,881.1 million representing a year on year increase of 147.4%.
Full year 2022 revenue guidance reaffirmed in the range of $7,770 - $8,050 million, representing a year over year increase of 41.8% - 46.9%.
Full year 2022 adjusted earnings per share guidance reaffirmed in the range of $11.55 - $11.95. Adjusted earnings per share to exclude amortization, stock compensation, foreign exchange and transaction-related / integration-related adjustments.